[18F]FDG PET as a substitute for second-look laparotomy in patients with advanced ovarian carcinoma.
The aim of this study was to compare the prognostic value of fluorine-18 fluorodeoxyglucose positron emission tomography (FDG PET) with that of second-look laparotomy (SLL) in patients with advanced ovarian carcinoma following primary chemotherapy. Fifty-five patients who had undergone cytoreductive surgery and adjuvant chemotherapy for advanced ovarian carcinoma were enrolled in the study. Thirty patients underwent SLL after primary treatment (SLL group), while 25 underwent FDG PET after primary treatment without SLL (PET group) We retrospectively reviewed the medical records of the 55 patients for comparison of progression-free interval and disease-free interval between the two groups. Ovarian carcinomas recurred in 37 of the 55 patients. When the progression-free interval and the disease-free interval in patients in the PET group were compared with those in the SLL group, no significant differences were observed. The progression-free interval in the PET and SLL groups were 28.8 +/- 12.7 months and 30.6 +/- 13.7 months, respectively (P = 0.29). The disease-free interval in the negative PET group was 40.5 +/- 11.6 months, and that in the negative SLL group was 48.6 +/- 12.1 months (P = 0.12). In conclusion, FDG PET has a similar prognostic value to SLL, and can substitute for SLL in the follow-up of patients who have had ovarian carcinoma, especially when there is a high risk for recurrence.
Kim
Sungeun
S
Department of Nuclear Medicine, Seoul National University Hospital, Chongno-gu, Seoul, Korea.
Chung
June-Key
JK
Kang
Soon-Beom
SB
Kim
Moon-Hong
MH
Jeong
Jae Min
JM
Lee
Dong Soo
DS
Lee
Myung Chul
MC
D000328:Adult; D000368:Aged; D000700:Analgesics / Q000627:therapeutic use; D018572:Disease-Free Survival; D005260:Female; D019788:Fluorodeoxyglucose F18; D005500:Follow-Up Studies; D006801:Humans; D007723:Korea / Q000453:epidemiology; D007813:Laparotomy / Q000379:methods; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000000981:diagnostic imaging* / Q000188:drug therapy / Q000401:mortality / Q000601:surgery*; D010051:Ovarian Neoplasms / Q000000981:diagnostic imaging* / Q000188:drug therapy / Q000401:mortality / Q000601:surgery*; D011379:Prognosis; D019275:Radiopharmaceuticals; D015203:Reproducibility of Results; D024162:Second-Look Surgery / Q000379:methods*; D012680:Sensitivity and Specificity; D014055:Tomography, Emission-Computed / Q000379:methods*; D016896:Treatment Outcome
D000700:Analgesics; D019275:Radiopharmaceuticals; D019788:Fluorodeoxyglucose F18